1. Home
  2. VIR vs NYAX Comparison

VIR vs NYAX Comparison

Compare VIR & NYAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • NYAX
  • Stock Information
  • Founded
  • VIR 2016
  • NYAX 2005
  • Country
  • VIR United States
  • NYAX Israel
  • Employees
  • VIR N/A
  • NYAX N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • NYAX
  • Sector
  • VIR Health Care
  • NYAX
  • Exchange
  • VIR Nasdaq
  • NYAX Nasdaq
  • Market Cap
  • VIR 1.0B
  • NYAX 951.9M
  • IPO Year
  • VIR 2019
  • NYAX N/A
  • Fundamental
  • Price
  • VIR $7.47
  • NYAX $27.78
  • Analyst Decision
  • VIR Buy
  • NYAX Buy
  • Analyst Count
  • VIR 5
  • NYAX 6
  • Target Price
  • VIR $36.40
  • NYAX $31.25
  • AVG Volume (30 Days)
  • VIR 1.4M
  • NYAX 9.4K
  • Earning Date
  • VIR 02-20-2025
  • NYAX 11-12-2024
  • Dividend Yield
  • VIR N/A
  • NYAX N/A
  • EPS Growth
  • VIR N/A
  • NYAX N/A
  • EPS
  • VIR N/A
  • NYAX N/A
  • Revenue
  • VIR $78,618,000.00
  • NYAX $291,649,000.00
  • Revenue This Year
  • VIR N/A
  • NYAX $42.15
  • Revenue Next Year
  • VIR N/A
  • NYAX $28.97
  • P/E Ratio
  • VIR N/A
  • NYAX N/A
  • Revenue Growth
  • VIR N/A
  • NYAX 32.68
  • 52 Week Low
  • VIR $6.56
  • NYAX $18.75
  • 52 Week High
  • VIR $13.09
  • NYAX $30.99
  • Technical
  • Relative Strength Index (RSI)
  • VIR 45.87
  • NYAX 49.04
  • Support Level
  • VIR $7.15
  • NYAX $26.80
  • Resistance Level
  • VIR $7.56
  • NYAX $28.47
  • Average True Range (ATR)
  • VIR 0.40
  • NYAX 0.79
  • MACD
  • VIR -0.02
  • NYAX -0.02
  • Stochastic Oscillator
  • VIR 24.79
  • NYAX 31.90

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About NYAX Nayax Ltd.

Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform and integrated POS devices. The company address a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.

Share on Social Networks: